These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 31047111

  • 1. Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of ≥150-300 cells/μL.
    Yancey SW, Bradford ES, Keene ON.
    Respir Med; 2019 May; 151():139-141. PubMed ID: 31047111
    [Abstract] [Full Text] [Related]

  • 2. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, Brightling CE, Pavord ID.
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [Abstract] [Full Text] [Related]

  • 3. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M, Albers FC, Bratton DJ, Yancey SW, Liu MC, Hozawa S, Llanos JP, Kwon N.
    Respir Med; 2019 Jul; 154():69-75. PubMed ID: 31220806
    [Abstract] [Full Text] [Related]

  • 4. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma.
    Albers FC, Licskai C, Chanez P, Bratton DJ, Bradford ES, Yancey SW, Kwon N, Quirce S.
    Respir Med; 2019 Nov; 159():105806. PubMed ID: 31751853
    [Abstract] [Full Text] [Related]

  • 5. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
    Magnan A, Bourdin A, Prazma CM, Albers FC, Price RG, Yancey SW, Ortega H.
    Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
    Shimoda T, Odajima H, Okamasa A, Kawase M, Komatsubara M, Mayer B, Yancey S, Ortega H.
    Allergol Int; 2017 Jul; 66(3):445-451. PubMed ID: 28110896
    [Abstract] [Full Text] [Related]

  • 7. Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA.
    Albers FC, Papi A, Taillé C, Bratton DJ, Bradford ES, Yancey SW, Kwon N.
    Respir Res; 2019 Jul 30; 20(1):169. PubMed ID: 31362741
    [Abstract] [Full Text] [Related]

  • 8. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I, Stevenson M, Cooper K, Harnan S, Hamilton J, Clowes M, Carroll C, Harrison T, Saha S.
    Pharmacoeconomics; 2018 Feb 30; 36(2):131-144. PubMed ID: 28933002
    [Abstract] [Full Text] [Related]

  • 9. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
    Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, Yancey SW, Ortega HG.
    Clin Ther; 2016 Sep 30; 38(9):2058-2070.e1. PubMed ID: 27553751
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma.
    Yancey SW, Ortega HG, Keene ON, Bradford ES.
    Allergy Asthma Clin Immunol; 2019 Sep 30; 15():53. PubMed ID: 31507641
    [Abstract] [Full Text] [Related]

  • 11. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies.
    Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X.
    Curr Med Res Opin; 2017 Sep 30; 33(9):1605-1613. PubMed ID: 28644104
    [Abstract] [Full Text] [Related]

  • 12. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
    Gupta A, Ikeda M, Geng B, Azmi J, Price RG, Bradford ES, Yancey SW, Steinfeld J.
    J Allergy Clin Immunol; 2019 Nov 30; 144(5):1336-1342.e7. PubMed ID: 31425781
    [Abstract] [Full Text] [Related]

  • 13. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
    Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, Bratton DJ, Gunsoy NB.
    J Allergy Clin Immunol; 2019 Jan 30; 143(1):190-200.e20. PubMed ID: 30205189
    [Abstract] [Full Text] [Related]

  • 14. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
    McDowell PJ, Diver S, Yang F, Borg C, Busby J, Brown V, Shrimanker R, Cox C, Brightling CE, Chaudhuri R, Pavord ID, Heaney LG, Medical Research Council: Refractory Asthma Stratification Programme (RASP-UK Consortium).
    Lancet Respir Med; 2021 Oct 30; 9(10):1174-1184. PubMed ID: 33971168
    [Abstract] [Full Text] [Related]

  • 15. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
    Comberiati P, McCormack K, Malka-Rais J, Spahn JD.
    J Allergy Clin Immunol Pract; 2019 Oct 30; 7(8):2689-2696.e2. PubMed ID: 31201938
    [Abstract] [Full Text] [Related]

  • 16. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions.
    Gibson PG, Prazma CM, Chupp GL, Bradford ES, Forshag M, Mallett SA, Yancey SW, Smith SG, Bel EH.
    Respir Res; 2021 Jun 07; 22(1):171. PubMed ID: 34098955
    [Abstract] [Full Text] [Related]

  • 17. Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials.
    Lemiere C, Taillé C, Lee JK, Smith SG, Mallett S, Albers FC, Bradford ES, Yancey SW, Liu MC.
    Respir Res; 2021 Jun 22; 22(1):184. PubMed ID: 34158028
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies.
    Kim MK, Park HS, Park CS, Min SJ, Albers FC, Yancey SW, Mayer B, Kwon N.
    Korean J Intern Med; 2021 Mar 22; 36(2):362-370. PubMed ID: 32450626
    [Abstract] [Full Text] [Related]

  • 19. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.
    Katz LE, Gleich GJ, Hartley BF, Yancey SW, Ortega HG.
    Ann Am Thorac Soc; 2014 May 22; 11(4):531-6. PubMed ID: 24606022
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma.
    Gunsoy NB, Cockle SM, Yancey SW, Keene ON, Bradford ES, Albers FC, Pavord ID.
    J Allergy Clin Immunol Pract; 2018 May 22; 6(3):874-882.e4. PubMed ID: 29258789
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.